🏛️ Verified NIH Record • Updated 2026-02-12

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (NCT05987332)

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: IDEAYA Biosciences

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (17 items).

Location: Honor Health — Scottsdale, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11
  • Concurrent malignant disease
  • AEs from prior anti-cancer therapy that have not resolved to Grade ≤1
  • Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids
  • High risk of syncope or falls
  • Known AIDS related illness
  • Active adrenal insufficiency, active colitis, or active inflammatory bowel disease
  • History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids
  • Active infection requiring systemic antibiotic therapy or active Hepatitis B/C
  • Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug
  • Females who are pregnant or breastfeeding

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (68 Sites)

Showing the first 25 of 68 sites.

  • Honor Health — Scottsdale, Arizona
  • Moores Cancer Center — La Jolla, California
  • UCLA Medical Center — Los Angeles, California
  • The Angeles Clinic and Research Institute — Los Angeles, California
  • California Pacific Medical Center (CPMC) — San Francisco, California
  • University of California San Francisco — San Francisco, California
  • University of Colorado Cancer Center — Aurora, Colorado
  • SCRI at HealthONE — Denver, Colorado
  • University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Northside Hospital Atlanta — Atlanta, Georgia
  • University of Iowa — Iowa City, Iowa
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • The Cancer and Hematology Centers — Grand Rapids, Michigan
  • Minnesota Oncology Hematology, P.A. — Burnsville, Minnesota
  • Mayo Clinic — Rochester, Minnesota
  • Washington University School of Medicine — St Louis, Missouri
  • Roswell Park Cancer Institute — Buffalo, New York
  • Northwell Health — Manhasset, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Duke University Health System — Durham, North Carolina
  • University of Cincinnati — Cincinnati, Ohio
  • The Cleveland Clinic Foundation — Cleveland, Ohio
  • Thomas Jefferson University — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Uveal Melanoma

Explore by condition: All Metastatic Uveal Melanoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗